Advanced Solid Malignancies – Innovent CIBI363A202

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

Inclusion Criteria:

• Subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
• Male or female subjects ≥ 18 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
• Anticipated life expectancy of ≥ 3 months;
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.